< 生产厂家价格 >

布雷菲德菌素A

布雷菲德菌素A用途

Brefeldin A是蛋白质运输 (protein trafficking) 的特异性抑制剂,其阻断蛋白质从内质网向高尔基复合体的转运。

点击显示

布雷菲德菌素A名称

[ CAS 号 ]:
20350-15-6

[ 中文名 ]:
布雷非德菌素 A

[ 英文名 ]:
Brefeldin A

[中文别名 ]:

[英文别名 ]:

Brefeldin
Synergisidin
Brefeldin A
cyanein
Cyanaein
Brefeldin-A
MFCD00083258
ASCOTOXIN
decumbin
BFA

布雷菲德菌素A生物活性

[ 描述 ]:

Brefeldin A是蛋白质运输 (protein trafficking) 的特异性抑制剂,其阻断蛋白质从内质网向高尔基复合体的转运。

[ 相关类别 ]:

信号通路 >> 自噬 >> 自噬

信号通路 >> 细胞周期/DNA损伤 >> CRISPR/Cas9

信号通路 >> 自噬 >> 自噬

天然产物 >> 其他

研究领域 >> 癌症

[ 靶点 ]

CRISPR/Cas9

[体外研究]

布雷菲德菌素A治疗15小时或40小时,引起内质网(ER)的显着肿胀并将其定位转移至正常大鼠肾(NRK)细胞的外周。延长的布雷菲德菌素A治疗导致MT和肌动蛋白细胞骨架的显着破坏[1]。 BARS的ADP-核糖基化通过在布雷菲德菌素A和ADPR之间形成缀合物来介导。当与来自BFA处理的CD38 + HeLa细胞的培养基一起孵育时,BARS显示BAC结合[2]。 Brefeldin A在MDA-MB-231乳腺癌细胞中诱导不依赖贴壁的细胞死亡,抑制3D和2D培养物中MDA-MB-231集落的形成,并抑制MDA-MB的迁移和MMP 9(Matrix Metallopeptidase 9)活性-231 [3]。

[细胞实验]

将细胞在玻璃盖玻片上生长，在PBS中的3％多聚甲醛中固定（在室温下10分钟），然后在PBS中洗涤。在室温下用PBS中的0.01％Triton X-100透化细胞7分钟。将盖玻片洗涤（在PBS / 0.2％吐温中3次），在PBS / O.4％鱼皮明胶/0.2%吐温（5分钟）和PBS / 2.5％山羊血清/0.2%吐温（5分钟）中孵育。。封闭后，将细胞与一抗在37℃温育45分钟，然后用PBS / 0.2％吐温洗涤（5次，每次5分钟）。在37℃下加入第二抗体30分钟，然后如上洗涤细胞。将盖玻片以9：1甘油/ PBS与0.1％邻苯二胺的载玻片安装在载玻片上。

[参考文献]

[1]. Alvarez C, et al. Brefeldin A (BFA) disrupts the organization of the microtubule and the actin cytoskeletons. Eur J Cell Biol. 1999 Jan;78(1):1-14.

[2]. Colanzi A, et al. Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9794-9.

[3]. Tseng CN, et al. Brefeldin A reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014 Oct 29;19(11):17464-77.

[4]. Wang J, et al. Erythroleukemia cells acquire an alternative mitophagy capability. Sci Rep. 2016 Apr 19;6:24641.

[5]. Yu C, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015 Feb 5;16(2):142-7.

[相关活性小分子]

布雷菲德菌素A物理化学性质

[ 密度 ]:
1.1±0.1 g/cm3

[ 沸点 ]:
492.7±45.0 °C at 760 mmHg

[ 熔点 ]:
200-205ºC

[ 分子式 ]:
C₁₆H₂₄O₄

[ 分子量 ]:
280.359

[ 闪点 ]:
180.8±22.2 °C

[ 精确质量 ]:
280.167450

[ PSA ]:
66.76000

[ LogP ]:
1.61

[ 外观性状 ]:
白色固体

[ 蒸汽压 ]:
0.0±2.8 mmHg at 25°C

[ 折射率 ]:
1.513

[ 储存条件 ]:
2~8°C

布雷菲德菌素AMSDS

详细MSDS(安全技术说明书)

布雷菲德菌素A毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GY8410000

CHEMICAL NAME :: 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a-beta,12,13,14,14a-alpha-decahydro-1- beta-13-alpha-dihydroxy-6-beta-methyl-

CAS REGISTRY NUMBER :: 20350-15-6

LAST UPDATED :: 199412

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C16-H24-O4

MOLECULAR WEIGHT :: 280.40

WISWESSER LINE NOTATION :: T5-13- IVO GU OUTJ CQ FQ K1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Rodent - mouse Cells - not otherwise specified

DOSE/DURATION :: 200 ug/L

REFERENCE :: JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968- Volume(issue)/page/year: 39,1148,1986

点击显示

布雷菲德菌素A安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301

[ 警示性声明 ]:
P301 + P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;half-mask respirator (US);multi-purpose combination respirator cartridge (US)

[ 危害码 (欧洲) ]:
Xn: Harmful;T: Toxic;

[ 风险声明 (欧洲) ]:
R25

[ 安全声明 (欧洲) ]:
24/25-45-36-26

[ 危险品运输编码 ]:
UN 2811 6

[ WGK德国 ]:
3

[ RTECS号 ]:
GY8410000

[ 危险类别 ]:
6.1

[ 海关编码 ]:
29411090

布雷菲德菌素A合成路线

详细合成路线

布雷菲德菌素A上下游产品

布雷菲德菌素A上游产品

布雷菲德菌素A下游产品

布雷菲德菌素A文献

Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis.

MBio 5(5) , e01921-14, (2014)

Pathogenic and nonpathogenic species of bacteria and fungi release membrane vesicles (MV), containing proteins, polysaccharides, and lipids, into the extracellular milieu. Previously, we demonstrated ...

Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.

J. Virol. 89(5) , 2698-709, (2015)

CD4(+) T lymphocytes play a central role in the immune system and mediate their function after recognition of their respective antigens presented on major histocompatibility complex II (MHCII) molecul...

Effector CD8+ T cells are generated in response to an immunodominant epitope in type III effector YopE during primary Yersinia pseudotuberculosis infection.

Infect. Immun. 82(7) , 3033-44, (2014)

YopE is a virulence factor that is secreted into host cells infected by Yersinia species. The YopE C-terminal domain has GTPase-activating protein (GAP) activity. The YopE N-terminal domain contains a...

更多文献